Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
COVID-19 peptide trials
5 selected ClinicalTrials.gov records carrying the official condition label COVID-19. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
5 selected records.
4 profiles.
2022–2026 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 102 selected PubMed records and 13 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern COVID-19 unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT04382755
PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- September 14, 2023
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT04397718
PeptideScanner retained ClinicalTrials.gov record NCT04397718 at 2026-11-15T21:52:09.579Z. Its registry update date was 2022-06-06, and PeptideScanner's reviewed identity mapping was degarelix.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- June 6, 2022
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT04428008
PeptideScanner retained ClinicalTrials.gov record NCT04428008 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- April 21, 2026
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Thymosin alpha-1 · 2026-04-21
ClinicalTrials.gov record NCT04428008
Completed at the retained observation.
Open attributed record →Icatibant · 2026-03-16
ClinicalTrials.gov record NCT04488081
Active, not recruiting at the retained observation.
Open attributed record →Zilucoplan · 2023-09-14
ClinicalTrials.gov record NCT04382755
Completed at the retained observation.
Open attributed record →Zilucoplan · 2022-06-29
ClinicalTrials.gov record NCT04590586
Completed at the retained observation.
Open attributed record →Degarelix · 2022-06-06
ClinicalTrials.gov record NCT04397718
Completed at the retained observation.
Open attributed record →